Exelixis (EXEL) Shares are Up 13.11%

Exelixis (EXEL) : Traders are bullish on Exelixis (EXEL) as it has outperformed the S&P 500 by a wide margin of 25.73% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 12.51%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 13.11% in the last 1 week, and is up 23.18% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 16.2% and the 50-Day Moving Average is 32.13%.The 200 Day SMA reached 111.84% Exelixis, Inc. is up 78.29% in the last 3-month period. Year-to-Date the stock performance stands at 140.25%.


Exelixis (EXEL) : The consensus price target for Exelixis (EXEL) is $11.67 for the short term with a standard deviation of $3.51. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $15, however, the pessimist price target for the company is $8.

For the current week, the company shares have a recommendation consensus of Buy. Exelixis (NASDAQ:EXEL): The stock opened at $13.3 and touched an intraday high of $13.665 on Friday. During the day, the stock corrected to an intraday low of $13.1, however, the bulls stepped in and pushed the price higher to close in the green at $13.55 with a gain of 1.57% for the day. The total traded volume for the day was 8,480,231. The stock had closed at $13.55 in the previous trading session.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *